Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Vertex Pharmaceuticals Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$542.63-0.8%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Vertex develops and sells medicines for cystic fibrosis, inherited blood disorders, acute pain, and other serious diseases.
Company outlook: revenue of $13.2B to $13.3B for Fiscal year 2026 — up 10.0% on a year earlier